Close

H.C. Wainwright Starts Oncothyreon (ONTY) at Buy

October 21, 2014 7:20 AM EDT
Get Alerts ONTY Hot Sheet
Price: $1.21 --0%

Rating Summary:
    7 Buy, 2 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE

H.C. Wainwright initiated coverage on Oncothyreon (NASDAQ: ONTY) with a Buy rating and a price target of $4.00.

Analyst Reni Benjamin said, "Oncothyreon’s biotechnology franchise is comprised of diverse set of therapeutics including ONT-380, a potent and highly specific tyrosine kinase inhibitor targeting HER2, as well as ONT-10, an immunotherapy vaccine targeting MUC1. Additionally, the company’s recent acquisition of Alpine Biosciences brings a novel drug-delivery platform in-house, which we believe could be utilized to generate multiple therapeutic candidates in a wide variety of indications, including orphan diseases. Given the company’s burgeoning pipeline, ability to secure multiple partnerships and strong cash position of approximately $91.2 MM (pro forma), which we expect to last till 2H16, we believe Oncothyreon represents an undervalued player with significant upside for the long-term investor."

For an analyst ratings summary and ratings history on Oncothyreon click here. For more ratings news on Oncothyreon click here.

Shares of Oncothyreon closed at $1.73 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Definitive Agreement